Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.

Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2024 issues

Clinical pathology selected abstracts

December 2024—Excitement over the impact of artificial intelligence-based tools in different areas of health care has prompted position papers and research on the application of these new devices. One such tool is ChatGPT, which is publicly available and has demonstrated domain-specific knowledge in numerous areas, including medicine. The vast amount of data generated with current technologies, including digital pathology applications, and in subspecialty areas of pathology may lend itself to interpretation with artificial intelligence-based algorithms. But while AI-based applications can automate routine tasks and enhance diagnostic accuracy, their widespread use has been limited. Further AI research and validation of AI-based applications will increase adoption of such technology and, thereby, the overall efficiency and accuracy of the diagnostic process in pathology.

Anatomic pathology selected abstracts

December 2024—Recurrence of Crohn’s disease within one or two years of resection is common. The authors conducted a study in which they sought to identify histologic features in Crohn’s disease resections that may predict earlier recurrence (18 months or less) to potentially guide postoperative management. They performed a single-institution, retrospective database review of 41 patients who had first-time Crohn’s disease bowel resection specimens collected between October 2002 and December 2007. Patient demographics and Crohn’s disease course were documented. Slides were reviewed for the distribution and composition of inflammation, small bowel pyloric metaplasia, and the presence and characteristics of submucosal fibrosis and granulomas.

Molecular pathology selected abstracts

December 2024—Acute promyelocytic leukemia is generally characterized by presence of the PML::RARA fusion. However, a subset of cases with morphological, cytochemical, and immunophenotypic features of acute promyelocytic leukemia (APL) lack this canonical fusion gene and instead present with alternate fusions. These include RARA fusions with partners other than PML and fusions involving other retinoic acid receptor (RAR) genes, such as RARG. Leukemias with these variant fusions often resist all-trans retinoic acid (ATRA) therapy. Specifically, the ATRA sensitivity of RARA fusion genes varies based on its 5′ fusion partner. Interestingly, in some studies, the artificially induced variant RAR bipartite fusion genes responded well to ATRA.

Newsbytes

December 2024—In a casual water cooler conversation, while standing around a coagulation analyzer to be precise, Lisa Daniel listened to her laboratory colleagues and a hospitalist, who happened to stop by the department, discuss their frustration with duplicate and other unnecessary tests. This led her to start a small committee, which in eight years has sextupled in size and undertaken numerous cost-saving measures.

Q&A column

December 2024
Q. What are the preferred tests for chronic kidney disease (CKD) screening and classification? Read answer.
Q. Is there a formula to correct a white blood cell count for micromegakaryocytes, or are megakaryocytes considered clinically insignificant unless there are greater than five per 100 WBCs? Is there a movement to drop reporting percents for individual WBCs, reactive lymphocytes, and reticulocytes? If so, does the CAP support such a change? Read answer.

Put It on the Board

December 2024—In a white paper released this fall, the CAP sets forth five recommendations to address private health insurers’ interference in patient-physician and physician-physician relationships by limiting the number of in-network physicians or exclusively contracting with particular providers and facilities. In the paper, “Examining the State of Health Care’s Private Payers and the Adverse Impact of Insurance Interference,” the CAP says “Two-thirds of the country’s population is covered by private health insurance, yet the coverage provided is less and less meaningful.”

Rethinking maternal AFP race adjustments

November 2024—David Grenache, PhD, D(ABCC), chief scientific officer of TriCore, is breaking no new ground when he considers the maternal serum alpha-fetoprotein test and says, “A screening test is designed to put people into one of two camps.” No scientific advances there. But the reverberations of this particular screening test have landed patients and physicians in complicated situations of late. The obvious divide is to identify increased risk of fetal abnormalities, including open neural tube defects. But the test has historically incorporated a race adjustment for Black patients. And that adjustment—seen as a way to account for reported differences in AFP values between Black and non-Black pregnant persons—in turn has come under more scrutiny recently as physicians question whether the adjustment should continue to be used, or whether it should be dropped, à la the race adjustment for eGFR/renal function. Compared with eGFR, evaluating the race adjustment in maternal serum AFP screening is more in its infancy, Dr. Grenache says.

Respiratory virus readiness, H5N1 ramp-up

November 2024—When it comes to what diseases are predicted to circulate and when, expect a respiratory virus season much like last year’s, and the year before that. As for the severity? “That’s anybody’s guess,” says Alesia McKeown, PhD, scientific partner, medical and scientific affairs at Roche Diagnostics, speaking in late September.

MARKETPLACE

TRENDING